Handelsbanken Fonder AB Purchases 47,052 Shares of Amgen Inc. $AMGN

Handelsbanken Fonder AB boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 15.7% during the second quarter, Holdings Channel reports. The institutional investor owned 346,596 shares of the medical research company’s stock after acquiring an additional 47,052 shares during the quarter. Handelsbanken Fonder AB’s holdings in Amgen were worth $125,509,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Adell Harriman & Carpenter Inc. increased its position in shares of Amgen by 7.9% during the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after purchasing an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Amgen in the fourth quarter valued at about $22,441,000. Sigma Planning Corp boosted its position in Amgen by 24.0% in the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock valued at $5,889,000 after buying an additional 3,488 shares in the last quarter. Integrated Advisors Network LLC grew its stake in Amgen by 50.5% during the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock worth $6,664,000 after buying an additional 6,356 shares during the last quarter. Finally, National Pension Service grew its stake in Amgen by 4.7% during the fourth quarter. National Pension Service now owns 1,239,549 shares of the medical research company’s stock worth $405,717,000 after buying an additional 55,489 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Amgen stock opened at $417.20 on Tuesday. The company has a market cap of $225.55 billion, a PE ratio of 25.93, a PEG ratio of 3.82 and a beta of 0.41. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $418.40. The company’s 50-day moving average is $364.54 and its two-hundred day moving average is $357.03.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts anticipate that Amgen Inc. will post 22.78 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s payout ratio is currently 62.65%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of research analyst reports. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Truist Financial boosted their target price on Amgen from $340.00 to $362.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Erste Group Bank restated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Citigroup raised their price target on Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a report on Friday. Finally, TD Cowen boosted their price objective on Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Amgen has an average rating of “Hold” and a consensus price target of $371.68.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.